Latest Period
Q4 2025
Security Snapshot
Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 (LXEO) Institutional Ownership
CUSIP: 52886X107
13F Institutional Holders and Ownership History from Q4 2023 to Q1 2026
Institutions Reporting
145
Shares (Excl. Options)
76,464,347
Price
$9.93
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common stock, par value $0.0001
- Symbol
- LXEO on Nasdaq
- Shares outstanding
- 73,698,416
- Price per share
- $5.74
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 76,464,347
- Total reported value
- $759,231,269
- % of total 13F portfolios
- 0%
- Share change
- +26,742,063
- Value change
- +$269,440,349
- Number of holders
- 145
- Price from insider filings
- $5.74
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- LXEO - Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 is tracked under CUSIP 52886X107.
- 145 institutions reported positions in Q4 2025.
- 17 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 145 to 31 between Q4 2025 and Q1 2026.
- Reported value moved from $759,231,269 to $15,303,113.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 145 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 52886X107?
CUSIP 52886X107 identifies LXEO - Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 52886X107:
Significant Owners of Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 (LXEO) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 10% | -12% | $65,914,563 | +$10,720,599 | 7,291,434 | +19% | JANUS HENDERSON GROUP PLC | 28 Nov 2025 |
| BALYASNY ASSET MANAGEMENT L.P. | 9.9% | -1% | $53,656,154 | +$13,573,377 | 7,221,555 | +34% | Balyasny Asset Management L.P. | 31 Dec 2025 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 7.7% | $32,573,226 | 5,674,778 | SUVRETTA CAPITAL MANAGEMENT, LLC | 06 Apr 2026 | |||
| CITADEL ADVISORS LLC | 7.4% | -22% | $40,851,767 | +$1,219,315 | 5,498,219 | +3.1% | Kenneth Griffin | 31 Dec 2025 |
| Affinity Asset Advisors, LLC | 7.1% | -8.1% | $51,813,451 | +$9,589,340 | 5,217,660 | +23% | Affinity Asset Advisors, LLC | 22 Jan 2026 |
| RA CAPITAL MANAGEMENT, L.P. | 6.9% | $33,200,000 | 5,000,000 | RA Capital Management, L.P. | 20 Oct 2025 | |||
| BlackRock, Inc. | 6.7% | +68% | $48,518,087 | +$26,984,571 | 4,885,814 | +125% | BlackRock, Inc. | 31 Dec 2025 |
| Paradigm Biocapital Advisors LP | 6.5% | +30% | $35,390,561 | +$8,107,609 | 4,763,198 | +30% | Paradigm BioCapital Advisors LP | 31 Dec 2025 |
| Vestal Point Capital, LP | 7.5% | +25% | $27,338,885 | +$5,903,896 | 4,117,302 | +28% | Vestal Point Capital, LP | 30 Sep 2025 |
| Frazier Life Sciences Public Fund, L.P. | 5.1% | -10% | $27,478,154 | +$4,642,294 | 3,698,271 | +20% | Frazier Life Sciences Public Fund, L.P. | 31 Dec 2025 |
| Longitude Capital Partners IV, LLC | 3.8% | $18,362,130 | 2,765,381 | Longitude Capital Partners IV, LLC | 30 Sep 2025 | |||
| INTEGRATED CORE STRATEGIES (US) LLC | 3.2% | -42% | $15,362,583 | -$3,470,396 | 2,313,642 | -18% | Millennium Management LLC | 30 Sep 2025 |
| MIZUHO FINANCIAL GROUP INC | 6.6% | +13% | $8,109,362 | +$1,020,464 | 2,203,631 | +14% | Mizuho Financial Group, Inc. | 31 Mar 2025 |
| EVENTIDE ASSET MANAGEMENT, LLC | 3.7% | $4,544,189 | 1,234,834 | Eventide Asset Management, LLC | 31 Dec 2024 | |||
| Omega Fund VI, L.P. | 3.6% | $4,359,460 | 1,184,636 | Omega Fund VI, L.P. | 31 Dec 2024 | |||
| D1 Capital Partners L.P. | 2.9% | $3,601,439 | 978,652 | D1 Capital Partners L.P. | 31 Mar 2025 | |||
| Adage Capital Management, L.P. | 0.7% | -85% | $875,667 | -$7,255,716 | 237,953 | -89% | Adage Capital Management, L.P. | 31 Mar 2025 |
As of 31 Dec 2025, 145 institutional investors reported holding 76,464,347 shares of Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 (LXEO). This represents 104% of the company’s total 73,698,416 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 (LXEO) together control 90% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| JANUS HENDERSON GROUP PLC | 7.5% | 5,509,635 | -9.8% | 0.02% | $54,668,943 |
| RA CAPITAL MANAGEMENT, L.P. | 6.8% | 5,000,000 | 0.51% | $49,650,000 | |
| BlackRock, Inc. | 6.7% | 4,907,563 | +126% | 0% | $48,732,100 |
| Paradigm Biocapital Advisors LP | 6.5% | 4,763,198 | 1.3% | $47,298,556 | |
| Vestal Point Capital, LP | 6.1% | 4,475,000 | +38% | 1.6% | $44,436,750 |
| Frazier Life Sciences Management, L.P. | 6% | 4,424,725 | 0% | 1.2% | $43,937,519 |
| VANGUARD GROUP INC | 5.3% | 3,894,310 | +75% | 0% | $38,670,499 |
| CITADEL ADVISORS LLC | 5.1% | 3,774,317 | +1.5% | 0.03% | $37,478,968 |
| Avoro Capital Advisors LLC | 4.5% | 3,300,000 | 0.32% | $32,769,000 | |
| Affinity Asset Advisors, LLC | 4.3% | 3,200,000 | -17% | 2.3% | $31,776,000 |
| Woodline Partners LP | 4.3% | 3,197,760 | +24% | 0.12% | $31,753,757 |
| STATE STREET CORP | 4.3% | 3,187,722 | +485% | 0% | $31,654,079 |
| ORBIMED ADVISORS LLC | 2.9% | 2,125,000 | 0.45% | $21,101,250 | |
| Point72 Asset Management, L.P. | 2.6% | 1,894,722 | -2.4% | 0.03% | $18,814,589 |
| Octagon Capital Advisors LP | 2.3% | 1,725,000 | 2.1% | $17,129,250 | |
| Balyasny Asset Management L.P. | 2.2% | 1,635,026 | -58% | 0.03% | $16,235,808 |
| GEODE CAPITAL MANAGEMENT, LLC | 2% | 1,445,887 | +100% | 0% | $14,361,075 |
| ADAR1 Capital Management, LLC | 1.9% | 1,393,161 | -9.1% | 1% | $13,834,089 |
| SUVRETTA CAPITAL MANAGEMENT, LLC | 1.7% | 1,250,000 | 0.31% | $12,412,500 | |
| 683 Capital Management, LLC | 1.5% | 1,120,000 | +21% | 0.92% | $11,121,600 |
| Nantahala Capital Management, LLC | 1.4% | 1,000,000 | 0.59% | $9,930,000 | |
| MILLENNIUM MANAGEMENT LLC | 1.2% | 908,024 | -61% | 0.01% | $9,016,678 |
| Blackstone Inc. | 1.2% | 904,959 | -20% | 0.04% | $8,986,243 |
| DIMENSIONAL FUND ADVISORS LP | 1.2% | 862,892 | -5.4% | 0% | $8,567,932 |
| GOLDMAN SACHS GROUP INC | 1.1% | 781,855 | +449% | 0% | $7,763,820 |
Institutional Holders of Lexeo Therapeutics, Inc. - Common stock, par value $0.0001 (LXEO) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 2,666,577 | $15,303,113 | +$2,428,386 | $5.74 | 31 |
| 2025 Q4 | 76,464,347 | $759,231,269 | +$269,440,349 | $9.93 | 145 |
| 2025 Q3 | 49,322,779 | $327,479,655 | +$52,645,662 | $6.64 | 108 |
| 2025 Q2 | 42,272,843 | $169,997,165 | +$59,022,508 | $4.02 | 90 |
| 2025 Q1 | 28,007,948 | $99,996,757 | -$11,520,766 | $3.47 | 88 |
| 2024 Q4 | 29,519,159 | $194,192,987 | -$4,086,062 | $6.58 | 89 |
| 2024 Q3 | 29,735,114 | $268,784,046 | +$10,322,355 | $9.04 | 67 |
| 2024 Q2 | 26,566,622 | $426,105,401 | +$55,254,655 | $16.04 | 57 |
| 2024 Q1 | 23,119,889 | $361,545,010 | +$108,427,159 | $15.68 | 54 |
| 2023 Q4 | 16,174,480 | $217,090,546 | +$217,090,546 | $13.42 | 31 |